Raymond James assumed coverage on shares of Leap Therapeutics (NASDAQ:LPTX) in a research report report published on Friday morning, The Fly reports. The brokerage issued an outperform rating and a $5.00 price objective on the stock.
A number of other research analysts have also issued reports on the company. Zacks Investment Research raised Leap Therapeutics from a hold rating to a buy rating and set a $1.50 target price on the stock in a report on Friday, August 16th. ValuEngine upgraded Leap Therapeutics from a hold rating to a buy rating in a research note on Thursday, August 1st.
NASDAQ:LPTX opened at $1.82 on Friday. The firm has a market cap of $43.75 million, a P/E ratio of -0.73 and a beta of 2.51. The company has a current ratio of 1.99, a quick ratio of 1.99 and a debt-to-equity ratio of 0.07. The stock’s 50 day simple moving average is $1.69 and its 200-day simple moving average is $1.72. Leap Therapeutics has a 12-month low of $1.35 and a 12-month high of $8.17.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in shares of Leap Therapeutics by 40.0% in the second quarter. BlackRock Inc. now owns 34,233 shares of the company’s stock valued at $61,000 after buying an additional 9,782 shares in the last quarter. A.R.T. Advisors LLC purchased a new stake in Leap Therapeutics during the second quarter worth $28,000. Bank of New York Mellon Corp purchased a new stake in Leap Therapeutics during the second quarter worth $42,000. Deutsche Bank AG boosted its position in Leap Therapeutics by 45.7% during the fourth quarter. Deutsche Bank AG now owns 124,338 shares of the company’s stock worth $248,000 after purchasing an additional 39,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Leap Therapeutics by 183.4% during the second quarter. Vanguard Group Inc. now owns 555,195 shares of the company’s stock worth $994,000 after purchasing an additional 359,320 shares in the last quarter. Hedge funds and other institutional investors own 10.84% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
See Also: Straddles
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.